ANDA 204473, held by Zydus Pharms. Mycophenolate Mofetil Hydrochloride.
As of Nov 16, 2026, ANDA 204473 (Mycophenolate Mofetil Hydrochloride), held by Zydus Pharms, was first approved by FDA on Aug 31, 2017, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 31, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mycophenolate Mofetil Hydrochloride500MG/VIAL · injectable;injection | Mycophenolate Mofetil Hydrochloride | Rx |
| Jul 29, 2026 | Supplement 10REMS | Approved | None posted |
| Aug 13, 2024 | Supplement 9REMS | Approved | None posted |
| Aug 11, 2021 | Supplement 6REMS | Approved | None posted |
| Apr 21, 2021 | Supplement 5REMS | Approved | None posted |
| Jan 15, 2021 | Supplement 4REMS | Approved | None posted |
| Mar 5, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 5, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 31, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters